Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Other Accumulated Expenses for 3 consecutive years, with $59000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Other Accumulated Expenses fell 38.54% year-over-year to $59000.0, compared with a TTM value of $59000.0 through Mar 2024, down 38.54%, and an annual FY2023 reading of $59000.0, down 55.64% over the prior year.
  • Other Accumulated Expenses was $59000.0 for Q1 2024 at Oramed Pharmaceuticals, roughly flat from $59000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $169000.0 in Q1 2022 and bottomed at $59000.0 in Q3 2023.
  • Average Other Accumulated Expenses over 3 years is $108111.1, with a median of $96000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses crashed 55.64% in 2023, then tumbled 38.54% in 2024.
  • Year by year, Other Accumulated Expenses stood at $133000.0 in 2022, then crashed by 55.64% to $59000.0 in 2023, then changed by 0.0% to $59000.0 in 2024.
  • Business Quant data shows Other Accumulated Expenses for ORMP at $59000.0 in Q1 2024, $59000.0 in Q4 2023, and $59000.0 in Q3 2023.